Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications

Modern Pathology

Volumn 28, Issue 5, 2015, Pages 695-705

  Van Rhijn, Bas W G ^a,b,c,d   Musquera, Mireia ^a   Liu, Liyang ^c   Vis, André N ^b,d   Zuiverloon, Tahlita C M ^b,e   Van Leenders, Geert J L H ^e   Kirkels, Wim J ^b   Zwarthoff, Ellen C ^e   Boevé, Egbert R ^d   Jöbsis, Adriaan C ^d   Bapat, Bharati ^c   Jewett, Michael A S ^a   Zlotta, Alexandre R ^a,c   Van Der Kwast, Theo H ^e,f  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c MOUNT SINAI HOSPITAL   (Canada)

^d SINT FRANCISCUS GASTHUIS   (Netherlands)

^e JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^f UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; KI 67 ANTIGEN; PROTEIN P27; PROTEIN P53; TUMOR MARKER; FGFR3 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 3;

ADULT; ARTICLE; BCG VACCINATION; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER IMMUNIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FIBROBLAST GROWTH FACTOR RECEPTOR 3 GENE; GENE MUTATION; GENETIC ASSOCIATION; HOSPITAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MOLECULAR BIOLOGY; NON MUSCLE INVASIVE BLADDER CANCER; PATHOLOGIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; TUMOR GENE; UROLOGIST; VALIDATION STUDY; WORLD HEALTH ORGANIZATION; AGED; BLADDER TUMOR; CLASSIFICATION; DNA MUTATIONAL ANALYSIS; GENETICS; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY; POLYMERASE CHAIN REACTION; PROCEDURES; TRANSITIONAL CELL CARCINOMA;

AGED; CARCINOMA, TRANSITIONAL CELL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; POLYMERASE CHAIN REACTION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; URINARY BLADDER NEOPLASMS; WORLD HEALTH ORGANIZATION;

EID: 84928826808     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.154     Document Type: Article

References (34)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63: 11-30
2. Sobin DH, Wittekind Cheds. TNM Classification of Malignant Tumours, 6th edn. Wiley-Liss: New York; 2002, pp 199-202
3. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of non-muscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007; 178: 2314-2330
4. Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013; 64: 639-653
5. van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009; 56: 430-442
6. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49: 466-477
7. Fernandez-Gomez J, Solsona E, Unda M, et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol. 2008; 53: 992-1001
8. Busch C, Algaba F. The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems. Virchows Arch. 2002; 441: 105-108
9. Vajo Z, Francomano CA, Wilkin DJ. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: The achondroplasia family of skeletal dysplasias, Muenke craniosynostosis and Crouzon syndrome with acanthosis nigricans. Endocr Rev. 2000; 21: 23-39
10. Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999; 23: 18-20
11. Billerey C, Chopin DK, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001; 158: 1955-1959
12. van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol. 2003; 21: 1912-1921
13. Hernández S, López-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006; 24: 3664-3671
14. Burger M, van der Aa MN, van Oers JM, et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol. 2008; 54: 835-843
15. van Rhijn BW, Zuiverloon TCM, Vis AN, et al. Molecular Grade (FGFR3/MIB-1) and EORTC riskscores are predictive in primary non-muscle invasive bladder cancer. Eur Urol. 2010; 58: 433-441
16. van Rhijn BW, Lurkin I, Chopin DK, et al. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. Clin Cancer Res. 2003; 9: 257-263
17. Junker K, van Oers JM, Zwarthoff EC, et al. Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. Neoplasia. 2008; 10: 1-7
18. Shariat SF, Ashfaq R, Sagalowsky AI, et al. Predictive value of cell cycle biomarkers in non-muscle invasive bladder transitional cell carcinoma. J Urol. 2007; 177: 481-487
19. Eble J, Sauter G, Epstein J, et al. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press: Lyon, 2004
20. Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumours. International Classification of Tumours, No. 10. World Health Organization: Geneva, 1973; 21-31
21. Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol. 1998; 22: 1435-1448
22. Lopez-Beltran A, Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol. 2004; 46: 170-176
23. Hofmann T, Knüchel-Clarke R, Hartmann A, et al. Clinical implications of the 2004 WHO histological classification on non-invasive tumours of the urinary bladder. EAU-EBU Update Series. 2006; 4: 83-95
24. Harnden P A critical appraisal of the classification of urothelial tumours: time for a review of the evidence and a radical change? BJU Int. 2006; 99: 723-725
25. MacLennan GT, Kirkali Z, Cheng L. Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol. 2007; 51: 889-897
26. van Rhijn BW, van Leenders GJLH, Ooms ECM, et al. The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading. Eur Urol. 2010; 57: 1052-1057
27. Montironi R, Lopez-Beltran A, Scarpelli M, et al. 2004) World Health Organization classification of the noninvasive urothelial neoplasms: inherent problems and clinical reflections. Eur Urol Suppl. 2009; 8: 453-457
28. Pan CC, Chang YH, Chen KK, et al. Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancerspecific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases. Am J Clin Pathol. 2010; 133: 788-795
29. Otto W, Denzinger S, Fritsche HM, et al. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int. 2011; 107: 404-408
30. Holmäng S, Hedelin H, Anderström C, et al. Recurrence and progression in low grade papillary urothelial tumors. J Urol. 1999; 162: 702-707
31. Holmäng S, Andius P, Hedelin H, et al. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol. 2001; 165: 1124-1128
32. Cao D, Vollmer RT, Luly J, et al. Comparison of 2004 and 1973 World Health Organization grading systems and their relationship to pathologic staging for predicting long-Term prognosis in patients with urothelial carcinoma. Urology. 2010; 76: 593-599
33. Malmström P-U, Busch C, Norlen BJ. Recurrence, progression and survival in bladder cancer A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up. Scand J Urol Nephrol. 1987; 21: 185-195
34. Liedberg F, Lauss M, Patschan O, et al. The importance of being grade 3: WHO 1999 versus WHO 2004 pathologic grading. Eur Urol. 2012; 62: 620-623